Interest in an app for two-way risk communication (i.e. to report adverse drug reactions [ADRs] to national medicines agencies and to receive drug safety information) is high among healthcare professionals (HCPs) and patients.

The app should be a faster way to report ADRs than conventional reporting options and should preferably offer additional information about drug–drug interactions and previously reported ADRs.

Strategies to disseminate an app on two-way risk communication could focus on targeting HCPs and patients who already use a health app since these persons were particularly interested in the app.